Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 4/20 | 0.41 |
| ▸ | FNTB | P49356 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31662502 | 0.78 | KDM4E (0.61) | PTGDR2KDM4ECNR2 | |
| SCHEMBL23306643 | 0.78 | KDM4E (0.61) | PTGDR2KDM4ECNR2 | |
| SCHEMBL23318377 | 0.75 | POLB (0.39) | KDM4E | |
| SCHEMBL23318257 | 0.74 | RORC (0.38) | RORCNPY5RPTGDR2CNR2 | |
| SCHEMBL811819 | 0.74 | POLB (0.55) | KDM4E | |
| SCHEMBL32689427 | 0.74 | POLB (0.55) | KDM4E | |
| SCHEMBL23318348 | 0.73 | CREBBP (0.51) | FNTAFNTBKDM4E | |
| SCHEMBL23318385 | 0.71 | CNR2 (0.50) | CNR2 | |
| SCHEMBL23318338 | 0.70 | POLB (0.39) | — | |
| SCHEMBL11846379 | 0.70 | KRAS (0.43) | RORCNPY5RPTGDR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| WO-2021087096-A1 | P53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | TP53, TP53BP1, MDM2 | RORC 3664/4885NPY5R 4719/4885MAP2K7 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.